Gan

Top Medical News
Supplementation with essential amino acid improves liver health in adolescents with PCOS
Rachel Tang, 2 days ago
Short-term supplementation with a selective essential amino acid (EAA)-containing product significantly improved liver-related outcomes among female adolescents with polycystic ovarian syndrome (PCOS) in a recent study.
Paediatric-onset immune-mediated inflammatory diseases raise mortality risk
2 days ago
People with paediatric-onset immune-mediated inflammatory diseases (pIMID) have a roughly fourfold increased risk of death in adulthood, as suggested in a study.
Hepatic arterial infusion chemo improves OS vs TACE in large HCC
17 Apr 2024
Use of panobinostat in combination with vincristine and irinotecan chemotherapy provides effective tumour response in models developed from patients with high-risk, relapsed, and treatment-refractory hepatoblastoma (HB), according to a study.
GLP-1RAs may improve long-term liver outcomes in T2D patients with MASLD
17 Apr 2024
For patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis, treatment with glucagon-like peptide-1 receptor agonists helps reduce the risk of hepatic decompensation, portal hypertension, hepatocellular carcinoma, and liver transplantation, according to a study.
MMF trumps azathioprine for remission in treatment-naive AIH
Stephen Padilla, 16 Apr 2024
Treatment with mycophenolate mofetil (MMF) in combination with prednisolone results in better biochemical remission rates at 24 weeks than the use of azathioprine plus prednisolone in patients with treatment-naïve autoimmune hepatitis (AIH), reports a study.
Cancer survivors at risk of fractures
15 Apr 2024
Use of tenofovir disoproxil fumarate (TDF) for ≥24 months increases the risk of fracture in older patients with chronic hepatitis B (CHB), reports a study.
SGLT2 inhibitors suitable for patients with T2D and NAFLD
14 Apr 2024
Clinicians may favour prescribing sodium-glucose cotransporter 2 (SGLT2) inhibitors to patients with both type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD), with the drugs having potential benefits in terms of NAFLD regression and reduced incidences of adverse liver-related outcomes, according to a study.
Conference Reports
Aspirin reduces liver fat, improves markers of inflammation, fibrosis
Elvira Manzano, 04 Jan 2024
Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) – previously called nonalcoholic fatty liver disease (NAFLD) – but without  cirrhosis, who were treated with daily low-dose aspirin, had significant reductions in liver fat for 6 months in a new trial.
Resmetirom reduces bad cholesterol, restores thyroid hormones in NASH
Elaine Soliven, 12 Dec 2023

Treatment with resmetirom significantly reduced low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipids, as well as restored thyroid hormone (TH) levels in patients with nonalcoholic steatohepatitis (NASH), according to two subgroup analyses of the MAESTRO-NASH trial presented at The Liver Meeting 2023.

Seladelpar improves markers of cholestasis, reduces pruritus in patients with PBC
Elaine Soliven, 01 Dec 2023

Treatment with seladelpar significantly improves serum markers of cholestasis, including alkaline phosphatase (ALP) and total bilirubin (TB), and reduces pruritus in patients with primary biliary cholangitis (PBC) who are at risk for disease progression, according to the RESPONSE trial presented at The Liver Meeting 2023.

Novel tri-agonist confers significant gains for MASLD patients
Audrey Abella, 24 Nov 2023
In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.
HBV vaccine improves survival of patients with chronic liver disease
Stephen Padilla, 22 Nov 2023
Vaccination against hepatitis B virus (HBV) results in meaningful improvements in survival among patients with different kinds of chronic liver diseases, suggests a study presented at AASLD 2023.
Can elexacaftor/tezacaftor/ivacaftor cause liver damage in adults with cystic fibrosis?
Stephen Padilla, 21 Nov 2023
Treatment with elexacaftor/tezacaftor/ivacaftor (ETI) rarely results in severe drug-induced liver injury among adults with cystic fibrosis, as shown in a study presented at AASLD 2023. Moreover, serum markers of fibrosis have increased but remain within normal range.
Bulevirtide-PegIFNα combo yields benefits for CHD patients
Audrey Abella, 21 Nov 2023
A combination regimen comprising bulevirtide 10 mg (BLV10) and pegylated interferon alpha-2a (PegIFNα) improved multiple liver parameters in patients with chronic hepatitis delta (CHD), findings from the phase IIb MYR204 study have shown.